By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CyDex Pharmaceuticals 

10513 W. 84th Terrace

Lenexa  Kansas  66214  U.S.A.
Phone: 913-685-8850 Fax: 913-685-8856



Company News
Marinus Pharmaceuticals (MRNS) Enters Into Use Agreement With CyDex Pharmaceuticals For Use Of Captisol® For Ganaxolone IV 8/12/2014 7:38:07 AM
CyDex Pharmaceuticals Announces Captisol(R) Technology Used in Recently Approved New Premixed Bag Presentation of NEXTERONE(R) 11/19/2010 11:11:50 AM
CyDex Pharmaceuticals Obtains Full Development and Commercialization Rights to Novel Captisol-Enabled(R) Intravenous Formulation of Clopidogrel; Terminating Agreement with Prism Pharmaceuticals, Inc. 10/12/2010 7:37:22 AM
CyDex Pharmaceuticals Licenses New Cyclodextrin Derivative From University of Kansas 8/4/2010 9:30:28 AM
CyDex Pharmaceuticals Initiates Dosing for Phase 2A Oncology Drug Trial 3/22/2010 9:06:30 AM
CyDex Pharmaceuticals to Present at Cowen and Company's 30th Annual Health Care Conference 3/3/2010 10:28:48 AM
CyDex Pharmaceuticals Receives a Key U.S. Patent for Composition of Matter and Process of Manufacturing High-Purity Captisol(R) 1/5/2010 11:39:32 AM
CyDex Pharmaceuticals Receives U.S. Patent for New Captisol(R) 12/9/2009 9:14:44 AM
CyDex Pharmaceuticals Extends Agreement with Hovione 9/21/2009 8:56:05 AM
FDA Accepts CyDex Pharmaceuticals' IND Application for Oncology Drug 7/27/2009 9:29:00 AM